Merck: promising results for pneumococcal vaccine

(CercleFinance.com) - Merck today announced the results of a Phase 3 trial evaluating V116, its investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults.


In adults aged 50 and over (Cohort 1), V116 elicited non-inferior immune responses to PCV20 for the 10 serotypes common to both vaccines, as measured by serotype-specific geometric mean opsonophagocyte activity (AOP) titers (GMT) at day 30.

In adults aged 18 to 49 (Cohort 2), V116 elicited non-inferior (immunobridged) immune responses compared to adults aged 50 to 64, as assessed by serotype-specific AOP GMTs 30 days after vaccination.

In both cohorts, V116 had a comparable safety profile to PCV20.

"These results provide strong evidence for the immunogenicity of V116 versus standard care in the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults," said Dr. Eliav Barr, Senior Vice President, Head of Global Clinical Development and Chief Medical Officer, Merck Research Laboratories.


Copyright (c) 2023 CercleFinance.com. All rights reserved.